Biotechnology company Genentech recently announced the U.S. Food and Drug Administration approved Tecentric® plus chemotherapy as a treatment option for patients with PD-L1-positive, triple-negative metastatic breast cancer. The announcement marks the first immunotherapy regimen approved for breast cancer. (Genentech)
